GlycoNex, a biotechnology company developing glycan-targeted cancer immunotherapies, has signed a manufacturing agreement with UK-based contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions. The collaboration will enable clinical trial production of GlycoNex’s drug candidate, GNX102-ADC, in preparation for an
Sterling Pharma Solutions, a global contract development and manufacturing organisation (CDMO), has initiated the second phase of its expansion strategy at its Deeside, UK, facility with an investment exceeding £10 million. The expansion includes a new 2,300-square-foot suite aimed at
Sterling Pharma Solutions has announced a significant investment to enhance its antibody-drug conjugate (ADC) contract development and manufacturing services. The $3 million investment at the Germantown, WI facility aims to expand the company’s integrated ADC capabilities, marking a substantial step
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
